Validation of Cardiometry in Resuscitation of Patients Undergoing Liver Transplantation

NCT ID: NCT03228329

Last Updated: 2018-12-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-08-10

Study Completion Date

2018-09-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

aim of our study to validate electrical cardiometry readings against same readings by transoesophageal echo. we will validate stroke volume (SV) readings stroke volume variation(SVV), index of contractility.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Induction of anaesthesia will be by using propofol (2mg.kg) IV, fentanyl (1-2μg. kg) IV and atracurium (0.5 mg.kg) IV. Anaesthesia will be maintained with Sevoflurane adjusted between 1-2% in an air ⁄ oxygen mix (FiO2 0.6), fentanyl infusion at 1-2 μg.kg/h and atracurium infusion at 0.5 mg.kg/ h. Mechanical ventilation will be provided by using a Dräger anaesthesia machine (Dräger Primus®, Germany) using a tidal volume of 6-8 ml.kg with the respiratory rate adjusted to maintain the PaCO2 between 4-4.6 kilopascal (kPa) and positive end expiratory pressure (PEEP) of 5 cmH2O. All patients will be monitored for five lead ECG, peripheral oxygen saturation, noninvasive and invasive arterial blood pressure, temperature, end-tidal carbon dioxide tension, hourly urinary output, and central venous pressure (CVP). A 7-Fr triple lumen CVP catheter (Arrow International Inc, Reading, PA, USA) will be inserted into the right internal jugular vein.

All patients will receive 6ml /kg/h Ringer acetate solution as a maintenance intraoperative fluid. If SVV is more than 15%, the patient will be considered as fluid responder and will receive a 250-ml bolus of albumin 5% to maintain SVV ≤15%. Blood transfusion will be given based on a hemoglobin level (\< 7 g/dl). Norepinephrine will be administered if the mean arterial pressure was less than 70 mmHg. Epinephrine will be administered if mean arterial blood pressure was less than 70 mm Hg and the cardiac index was less than 2.5 L/min/m2 despite sufficient volume infusion, to maintain a target cardiac index of 2.5-3.0 L/min/m2

Electrical cardiometry (EC) Examination:

1. ECG electrodes will be placed on the bare skin of patients in the following positions:

1. On the left neck below the ear;
2. Directly above the midpoint of the left clavicle;
3. Along the left mid-axillary line at the level of the xiphoid process;
4. Two inches caudal from the third electrode.
2. Patient characteristics of sex, age, height and weight will be entered into the monitor.
3. Clocks on the EC and trans esophageal echo (TEE) machine will be synchronized prior to data collection.
4. The EC monitor will be programmed to capture moving averages of variables based on the previous 10 cardiac cycles and to record those averages every10 s.
5. Only EC data with a signal quality index (SQI) of \>70 will be included in the analysis.

Echo Examination:

1. A single LVOT diameter will be measured for each patient as the distance between the inflection points at the base of the aortic valve cusps from the left ventricle long axis view during systole.
2. Assuming a circular cross section, the LVOT area will be calculated from the LVOT diameter as:

π X (LVOT diameter/ 2)2 = (LVOT diameter)2 X 0.785
3. Pulse wave Doppler sampling cursor will be placed in the middle of the LVOT immediately proximal to the aortic valve in 5 chamber deep transgastric view.
4. The sonographer manually will trace the velocity-time envelope.
5. SV values will be identified for 10 cycles and averaged to obtain SV-Doppler max and SV-Doppler min. The mean SV (SV-Doppler mean) will be calculated as (SV-Doppler max - SV-Doppler min)/2.
6. SVV-Doppler will be calculated as (SV-Doppler max - SV-Doppler min)/SV-Doppler mean.
7. Peak aortic velocity, time to peak and mean acceleration will be calculated.

Mini Fluid challenge:

1. Mini fluid challenge will be done by 150 cc crystalloid over 1 min
2. 2 sets of measurement of SV and SVV will be obtained

1. The first set of measurement will be obtained before fluid challenge.
2. The second set will be obtained immediately after fluid challenge. Other data will be recorded as;heart rate (HR), systolic BP, Diastolic BP, mean BP, CVP and pulse pressure variation (PPV)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Transplantation

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

cardiometry stroke volume liver transplantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DEVICE_FEASIBILITY

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

cardiometry

fluid boluses will be given when there will be hypovolemia assessed by presence of pulse pressure variations

Group Type OTHER

fluid boluses

Intervention Type OTHER

fluid boluses will be given when there will be hypovolemia assessed by presence of pulse pressure variations

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

fluid boluses

fluid boluses will be given when there will be hypovolemia assessed by presence of pulse pressure variations

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ASA II to IV patients with end-stage liver disease
* patients undergoing orthotopic living donor liver transplantation
* age \> 18 years

Exclusion Criteria

* acute fulminant liver failure
* age \< 18 years
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kasr El Aini Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mohamed Elayashy Mohamed Ahmed Hassan

clinical professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

ahmed mohamed mokhtar, M.D

Role: STUDY_DIRECTOR

kasralainy faculty of medicine, Cairo university

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kasr Alainy Hospital , Faculty of Medicine

Cairo, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

References

Explore related publications, articles, or registry entries linked to this study.

Bechstein WO, Neuhaus P. [Bleeding problems in liver surgery and liver transplantation]. Chirurg. 2000 Apr;71(4):363-8. doi: 10.1007/s001040051066. German.

Reference Type BACKGROUND
PMID: 10840602 (View on PubMed)

Rossi G, Langer M, Maggi U, Reggiani P, Caccamo L, Gatti S, Paone G, Vannelli A, Prato P, Doglia M, Melada E, Latham L, Fassati LR. Veno-venous bypass versus no bypass in orthotopic liver transplantation: hemodynamic, metabolic, and renal data. Transplant Proc. 1998 Aug;30(5):1871-3. doi: 10.1016/s0041-1345(98)00465-5. No abstract available.

Reference Type BACKGROUND
PMID: 9723316 (View on PubMed)

Bulkley GB. Reactive oxygen metabolites and reperfusion injury: aberrant triggering of reticuloendothelial function. Lancet. 1994 Oct 1;344(8927):934-6. doi: 10.1016/s0140-6736(94)92276-4. No abstract available.

Reference Type BACKGROUND
PMID: 7848422 (View on PubMed)

Mukhtar AM, Elayashy M, Sayed AH, Obaya GM, Eladawy AA, Ali MA, Dahab HM, Khalaf DZ, Mohamed MA, Elfouly AH, Behairy GM, Abdelaal AA. Validation of electrical velocimetry in resuscitation of patients undergoing liver transplantation. Observational study. J Clin Monit Comput. 2020 Apr;34(2):271-276. doi: 10.1007/s10877-019-00313-z. Epub 2019 Apr 19.

Reference Type DERIVED
PMID: 31004273 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

N-43-2017

Identifier Type: -

Identifier Source: org_study_id